Ovation Science Secures Canadian Patent for Enhanced Cannabinoid Transdermal Delivery Technology
Key Insights
Ovation Science Inc. (search) has secured a new Canadian patent for proprietary topical formulations containing CBD and THC, expanding its intellectual property protection beyond its existing U.S. patent.
The patent protects Ovation's Invisicare (search)® drug delivery technology, which demonstrated CBD bioavailability of up to 82% compared to only 2-3% for competing transdermal products in laboratory testing.
With patents now secured in both the United States and Canada, the company is positioned to pursue licensing agreements across two major regulated cannabis markets.
Ovation Science Inc. (search) announced the issuance of a new Canadian patent covering proprietary topical formulations containing CBD and THC, significantly strengthening the company's international intellectual property portfolio. The patent, entitled "Composition and method for transdermal delivery of cannabidiol (CBD) and delta9-tetrahydrocannabinol (THC)," expands Ovation's intellectual property protection beyond its previously issued U.S. patent.
With patents now secured in both the United States and Canada, Ovation is positioned to pursue exclusive licensing agreements, strategic partnerships and product commercialization across two of the largest regulated cannabis markets in the world.
Enhanced Cannabinoid Delivery Performance
The Canadian patent protects Ovation's proprietary transdermal cannabinoid formulations, which are designed to efficiently deliver cannabinoids through the skin and into systemic circulation. These formulations are powered by Ovation's unique Invisicare (search)® drug delivery technology, which has demonstrated significantly enhanced cannabinoid absorption compared to conventional topical and transdermal products.
Comparative studies showed Ovation's products achieved CBD bioavailability of up to 82%, compared to only 2-3% for competing transdermal products. In contrast, oral CBD products such as gummies typically exhibit a low bioavailability of approximately 6%, as a significant portion of the CBD is lost during first-pass metabolism in the liver. These challenges are compounded by CBD's poor water solubility and limited stability—issues that Ovation's Invisicare (search)® formulations are specifically designed to overcome.
Strategic Commercial Positioning
"This patent represents a significant value-creation milestone for Ovation, our shareholders and licensees," said Terry Howlett, President of Ovation Science. "Securing Canadian patent protection strengthens our defensible IP position, increases the attractiveness of our technology to potential licensees, and expands our ability to generate recurring, non-dilutive revenue through licensing and branded product partnerships."
The company currently has four licensees in place and is positioned for revenue growth in 2026. As the regulatory framework continues to evolve in the USA with the rescheduling of cannabis to Schedule 3, Ovation believes it is uniquely positioned to capitalize on growing demand for effective topical cannabinoid solutions.
Scalable Technology Platform
Ovation's Invisicare (search) technology is supported by more than two decades of pharmaceutical research and is designed for scalability across multiple active ingredients, delivery formats, and regulated markets. In addition to Ovation's current cannabis formulations, Invisicare offers potential expansion into wellness, pharmaceutical, and other transdermal product categories along with topical beauty products, all using cannabinoids.
The performance differentiation supports premium product positioning and provides licensees with a compelling, efficacy-driven value proposition—key factors in driving adoption, repeat purchases, and long-term brand loyalty.
Ovation Science Inc. (search) and its wholly-owned subsidiary, Ovation Science USA Inc. (search), develops topical and transdermal CBD/THC and other cannabinoid products which are out-licensed to licensed operators by state or country. The company also distributes topical CBD products under its own brands, ARLO CBD Beauty and InVibe® MD, all powered by its patented Invisicare (search)® skin delivery technology. Ovation earns revenues from royalties on licensees' sales and the sale of Invisicare, along with revenue from its own product sales.